Suppr超能文献

21 年间一家三级医疗中心棘阿米巴角膜炎病例评估。

Evaluation of Acanthamoeba keratitis cases in a tertiary medical care centre over 21 years.

机构信息

Department of Ophthalmology, Medical University of Graz, 8036, Graz, Austria.

Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, 8036, Graz, Austria.

出版信息

Sci Rep. 2021 Jan 13;11(1):1036. doi: 10.1038/s41598-020-80222-3.

Abstract

To report on Acanthamoeba keratitis cases in a tertiary university eye-hospital in Graz, Austria, over a 21-year period. Retrospective study. Parameters included demographics, diagnostics, clinical courses, medical therapies, surgical interventions, secondary complications, and best spectacle-corrected visual acuity (BSCVA). Patient records for 44 eyes of 42 patients were analysed; 2 bilateral infections. Mean age at presentation was 31 ± 13 (16-65) years; contact lenses were used in 41 of 44 eyes (93.2%). Symptoms at initial presentation were mainly pain (41/43, 95.3%) and photophobia (16/43, 37.2%). Most frequent morphological findings were stromal infiltrates (30/44, 68.2%). Diagnosis was mainly confirmed by smears (40/42, 95.2%) and polymerase chain reaction (8/42, 19%). Antiamoebic treatment comprised biguanides and diamidines. Penetrating keratoplasty was performed in 10/44 (22.7%) eyes. Median time from symptom onset to initial visit was 2 (0-26) weeks; median follow-up was 30 (2-1008) weeks. BSCVA improved in 23/36 (63.9%) eyes, remained unchanged in 6/36 (16.7%) eyes and deteriorated in 7/36 (19.4%) eyes. Acanthamoeba keratitis predominantly occurs in young contact lens wearers. Diagnosis should be considered in patients with pain and stromal infiltrates. In the majority of cases, BSCVA can be improved. Early diagnosis and adequate treatment should be implemented to prevent complications.

摘要

报告在奥地利格拉茨的一家三级大学眼科医院 21 年来棘阿米巴角膜炎的病例。回顾性研究。参数包括人口统计学、诊断、临床病程、医学治疗、手术干预、继发并发症和最佳矫正视力(BSCVA)。分析了 42 例患者的 44 只眼的患者记录;2 例双眼感染。发病时的平均年龄为 31±13 岁(16-65 岁);44 只眼中有 41 只(93.2%)使用了隐形眼镜。初次就诊时的主要症状是疼痛(41/43,95.3%)和畏光(16/43,37.2%)。最常见的形态学发现是基质浸润(30/44,68.2%)。诊断主要通过涂片(40/42,95.2%)和聚合酶链反应(8/42,19%)确认。抗阿米巴治疗包括双胍类和二甲脒类。在 10/44 只(22.7%)眼中进行了穿透性角膜移植。从症状出现到首次就诊的中位数时间为 2(0-26)周;中位数随访时间为 30(2-1008)周。BSCVA 在 23/36(63.9%)只眼中改善,在 6/36(16.7%)只眼中保持不变,在 7/36(19.4%)只眼中恶化。棘阿米巴角膜炎主要发生在年轻的隐形眼镜佩戴者中。对于有疼痛和基质浸润的患者应考虑诊断。在大多数情况下,BSCVA 可以改善。应早期诊断和充分治疗,以防止并发症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e18c/7806847/3cd64af292a3/41598_2020_80222_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验